158.79
+5.25%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Guardant Health
From its filings with the US Securities and Exchange Commission
Guardant Health is based in Palo Alto, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker GH. The SEC classifies its business as medical laboratories. In the fiscal year to 31 December 2025, it reported revenue of $982.0m and a net loss of $416.3m. At that date it held total assets of $2.01bn and shareholders' equity of −$99.3m. By business, Oncology brought in 69.6% of revenue, followed by Biopharma and data at 21.4% and Screening at 8.1%.
We are a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. We are transforming patient care by providing critical insights into what drives disease through our advanced blood and tissue tests, real-world data and AI analytics. Our tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For patients with advanced-stage cancer, we offer the Guardant360 Liquid test, formerly known as the Guardant360 LDT test, and the Guardant360 CDx test, the first comprehensive liquid biopsy test approved by the U.S. Food and Drug Administration, or the FDA, to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer, or NSCLC, colorectal cancer and breast cancer. We also offer the Guardant360 Tissue test for advanced-stage cancer and the Guardant Reveal test to detect residual and recurring disease in early-stage colorectal, breast and lung cancer patients. We have also expanded the Guardant Reveal test to include late-stage therapy response monitoring for patients with solid tumors. Our product portfolio is now powered by our Smart Platform, which utilizes methylation technology with genomic, epigenomic, and RNA-based data, to unlock multi-modal biology with proprietary chemistry, advanced algorithms and our InfinityAI learning engine.
Quoted from its 10-K, filed 19 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 4 Oct 2018
- Employees
- 2,490
- Website
- guardanthealth.com ↗
- Head office
- 3100 HANOVER STREET, PALO ALTO, CA, 94304
- Incorporated in
- DE
- Classification
- Services-Medical Laboratories
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Helmy EltoukhyChairperson of the Board, Co-Chief Executive Officer, since 2013$11.6m
- Dr. Amirali TalasazCo-Chief Executive Officer, Director$11.6m
- Mr. Michael BellChief Financial Officer$3.6m
- Ms. Terilyn MonroeChief People Officer$5.5m
- Dr. Darya ChudovaChief Technology Officer$3.5m
- Mr. Kumud KaliaChief Information Officer
- Dr. Craig EagleChief Medical Officer$3.5m
- Mr. Christopher FreemanChief Commercial Officer$3.5m
- Mr. John SaiaChief Legal Officer, Corporate Secretary$3.2m
- Mr. Ian ClarkLead Independent Director$470,268
- Mr. Alex AzarDirector
- Ms. Vijaya GaddeIndependent Director$425,246
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 49
- Environment
- 33
- Social
- 71
- Governance
- 42
- Women in the workforce
- 54%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Proprietary liquid biopsy technology: Guardant Health Inc has developed advanced liquid biopsy technology, which allows for non-invasive genetic testing and enables early detection of cancer and other diseases.
- Strong brand reputation: Guardant Health has established a strong brand reputation within the healthcare industry for its innovative and reliable diagnostic tests.
- Strategic partnerships: The company has formed strategic partnerships with leading pharmaceutical companies and research institutions, enhancing its market presence and access to resources.
Weaknesses
- Reliance on key customers: Guardant Health Inc may face risks due to its dependence on a few key customers for a significant portion of its revenue, making its financial performance vulnerable to changes in customer demand or preferences.
- High research and development costs: Developing and improving liquid biopsy technology requires significant investment in research and development, which might strain the company's financial resources.
- Regulatory challenges: As a healthcare company dealing with genetic testing and diagnostic tools, Guardant Health Inc is subject to stringent regulations, which may delay product approvals or limit market expansion.
Opportunities
- Growing demand for precision medicine: With the increasing emphasis on personalized treatment approaches, Guardant Health Inc is well-positioned to benefit from the rising demand for precision medicine and targeted therapies.
- Expansion into international markets: Guardant Health Inc can explore opportunities to expand its presence in international markets, where there is an increasing need for advanced genetic testing and improved cancer diagnostics.
- Potential for partnerships with insurance providers: Collaborating with insurance providers to incorporate genetic testing as part of routine healthcare coverage could expand the customer base for Guardant Health Inc.
Threats
- Competitive landscape: The market for liquid biopsy and genetic testing is highly competitive, with the presence of established players as well as emerging startups. Guardant Health Inc may face intense competition, which could impact market share and pricing.
- Legal and ethical concerns: The use of genetic testing can raise privacy and ethical concerns. Guardant Health Inc needs to effectively address these issues to avoid potential legal challenges and maintain customer trust.
- Economic downturn and healthcare industry changes: Guardant Health Inc's financial performance can be influenced by economic downturns and fluctuations in the healthcare industry, which might affect funding and reimbursement policies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.